Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists ...

with a dual GLP-1R/ gastric inhibitory polypeptide receptor agonist having gained approval. Now, writing in Science Translational Medicine, Polex-Wolf et al. design a single-molecule dual agonist ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

LBT-3627 is under development for the treatment of Parkinson's disease. The drug candidate is administered through oral route. It is developed based on hybridtide scaffold technology. It acts by ...

Elon Musk has dished the secrets behind his recent weight loss transformation.

Amgen shared that it had positive interim results for its multispecific gastric inhibitory polypeptide receptor (GIPR) inhibitor MariTide (maridebart cafraglutide, AMG 133), which is being ...

Zepbound, however, is a dual-action drug that targets both the GLP-1 receptor and the GIP (gastric inhibitory polypeptide) receptor. This difference in approach could be one factor contributing to ...